Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease. by Wijeyekoon, Ruwani S et al.
1 
 
Cerebrospinal fluid cytokines and neurodegeneration-associated proteins in Parkinson’s 
Disease 
Ruwani S. Wijeyekoon MRCP, PhD1, Sarah F. Moore MB BChir1,6, Krista Farrell MRCP, MPhil1, 
David P. Breen MRCP, PhD2,3,4, Roger A. Barker MRCP, PhD1,5, Caroline H. Williams-Gray MRCP, 
PhD1  
1 John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of 
Cambridge, UK. 
2 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK 
3 Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, Scotland, UK 
4 Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, 
Scotland, UK 
5 Wellcome Trust-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK 
6 University of Exeter Medical School, University of Exeter, Exeter, UK 
*Corresponding author - Ruwani S. Wijeyekoon 
Address - John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University 
of Cambridge, E.D. Adrian Building, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK. 
Tel. – 01223 331160 
Email - rsw27@cam.ac.uk 
Word count – 1590 
Running Title - Cerebrospinal fluid in Parkinson’s Disease 
Key words – Parkinson’s disease, cerebrospinal fluid, cytokine, tau, alpha-synuclein 
Financial Disclosure/Conflicts of Interest - The authors report no conflicts of interests concerning 
the research related to the manuscript.   
Funding - Funding for this work was provided by the Rosetrees Trust (M369-F1), Addenbrooke’s 
Charitable Trust (PF15/CWG) and the NIHR Cambridge Biomedical Research Centre Dementia and 
Neurodegeneration Theme (146281). RSW was supported by a Fellowship from Addenbrooke’s 
Charitable Trust (RG77199). SFM was supported by the Transeuro EU FP7 grant (242003) and is now 
an NIHR Academic Clinical Fellow (ACF-2015-23-501). DPB is supported by a Wellcome Trust 
Clinical Research Career Development Fellowship (214571/Z/18/Z). RAB is an NIHR Senior 
Investigator (NF-SI-0616-10011) and is supported by the Wellcome Trust-MRC Cambridge Stem Cell 
2 
 
Institute (203151/Z/16/Z). CHWG holds a RCUK/UKRI Research Innovation Fellowship awarded by 





Introduction- Immune markers are altered in Parkinson’s disease (PD), but relationships between 
cerebrospinal fluid (CSF) and plasma cytokines, and associations with neurodegeneration-associated 
proteins remain unclear.  
 
Methods- CSF and plasma samples and demographic/clinical measures were obtained from 35 PD 
patients. CSF samples were analysed for cytokines (together with plasma), and for alpha-synuclein, 
amyloid beta(1-42) peptide, total tau and phospho(Thr231)-tau.  
 
Results- There were no CSF-plasma cytokine correlations. IL-8 was higher and IFN-γ, IL-10 and TNF-
α were lower in CSF versus plasma. In CSF, total tau correlated positively with IL-8 and IL-1β, while 
alpha-synuclein correlated positively with amyloid beta(1-42) and negatively with semantic fluency 
(known marker of PD dementia risk).   
 
Discussion- CSF and peripheral cytokine profiles in PD are not closely related. Associations between 
CSF IL-8 and IL-1β, and tau suggest CSF inflammatory changes may relate to tau pathology within 













Parkinson’s disease (PD) is associated with central and peripheral immune changes[1]. However, the 
relationships between these changes and central neurodegeneration are unclear. The cerebrospinal fluid 
(CSF) is in close contact with the central nervous system (CNS) and studying CSF immune markers 
and neurodegeneration-associated proteins, alongside paired plasma immune markers may provide 
additional insights into these relationships in PD.  
 
The key neurodegeneration-associated protein involved in PD is alpha-synuclein, with multiple factors 
leading to abnormal aggregation and pathology. CSF total alpha-synuclein concentration is generally 
decreased in PD compared to controls[2], possibly reflecting intracellular accumulation/aggregation. 
PD patients with cognitive impairment and dementia additionally  have decreased CSF amyloid beta 
and increased total tau levels[3].  
 
Increased levels of inflammatory cytokines (e.g. Interleukin(IL)-1β, IL-6, IL-18 and Tumour Necrosis 
Factor(TNF)-α) have been detected in PD CSF compared to controls[4][5][6] and many studies have 
reported elevated levels of inflammatory cytokines in the serum/plasma of  PD patients compared to 
controls[7]. A more ‘pro-inflammatory’ serum cytokine profile has further been associated with more 
rapid disease progression in early PD[8] and while peripheral cytokine transport across the blood-brain 
barrier, with mediation of microglial activation and neuronal damage, could impact on disease course, 
a consistent relationship between peripheral and central cytokine levels has not been demonstrated in 
PD. 
 
The relationships between CSF cytokine changes and neurodegeneration-associated protein levels are 
largely unknown. Currently, limited studies have investigated this in PD[9] and no studies have 
investigated CSF alpha-synuclein, amyloid beta, total tau and phospho-tau alongside CSF cytokines in 
a single PD cohort.  
 
This study aimed to examine the relationships between central and peripheral cytokine levels as well as 
CSF cytokine and neurodegeneration-associated protein associations in a well characterised moderate-












Ethical approval was obtained from the Cambridgeshire-2 Research Ethics Committee (08/H0308/331). 
Patients were recruited from the PD Research Clinic at the John van Geest Centre for Brain Repair in 
Cambridge. Following screening for contraindications to lumbar puncture, written informed consent 
was obtained. Clinical data gathered included demographic, medical/drug history, Movement Disorder 
Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Addenbrooke’s Cognitive 
Examination-Revised (ACE-R), semantic fluency (predictive of dementia in PD)[10] and Beck 
Depression Inventory (BDI) scores . 
 
Sample collection and processing 
Lumbar punctures were performed in the left lateral position at the L3/4 or 4/5 space using aseptic 
technique, 1% lignocaine as local anaesthetic and a 22G spinal needle. ~2-5 ml of CSF was collected. 
A subset of patients (n=22) had concurrent EDTA venous blood sampling.  
CSF samples were centrifuged at 3000g for 15 minutes. Supernatant was stored in ~500ul aliquots at  
-80ºC. Plasma was extracted from blood by centrifugation at 2000rpm for 15 minutes and stored at  
-80ºC.  
 
Cytokine and protein analysis 
Samples were analysed using the Mesoscale Discovery (MSD) electrochemiluminescence platform. 
Assays were performed in duplicate, at 1:2 dilution, according to the manufacturer’s instructions 
(https://www.mesoscale.com/)-V-PLEX Pro-inflammatory panel-1 cytokines (Interferon(IFN)-γ, 
Interleukin(IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, Tumour Necrosis Factor(TNF-α)) in 
CSF and plasma, and alpha-synuclein, phospho(Thr231)-tau, total tau and amyloid beta(1-42) in CSF. 
Plates were read using the MSD SECTOR Imager. Data was processed using MSD Discovery 












Data was analysed using IBM SPSS version 25 and Graph Pad Prism 7. Cytokine and protein variables 
within the CSF and plasma with assay-detected values in >75% of participants were included in the 
analysis. Log10 transformation was performed due to the non-parametric distribution of variables. 
Plasma and CSF cytokine profiles were compared using a repeated measures ANOVA and paired t-
tests, with Bonferroni correction for multiple testing as appropriate. Bivariate correlations were assessed 
between CSF cytokines and neurodegeneration-associated proteins, and between CSF markers and 
clinical measures. Variables with uncorrected significant correlations (p<0.05) were included in linear 





Demographic and clinical measures in the PD cohort (n=35) were expressed as Mean(Standard 
Deviation): age 65.4(7.6) years; gender 48.6% male; years of education 18.7(3.9); disease duration 
5.4(5.6) years; MDS-UPDRS part III (on treatment) 31.0(12.1); ACE-R score 90.3(9.4); BDI score 
9.1(7.7) and semantic fluency score 23.9(8.4).  
CSF samples from all patients and paired plasma samples from 22 patients were available for analysis.  
 
CSF and plasma cytokines 
The cytokines IFN-γ,IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70 and TNF-α in CSF, and IFN-γ, IL-6, IL-
8, IL-10 and TNF-α in plasma, had measurable values in >75% of the analysed samples and were used 
for further analysis.  
 
Bivariate analysis of the detected cytokines in both CSF and plasma (IFN-γ, IL-6, IL-8, IL-10 and TNF-
α) indicated no correlations between CSF and plasma levels in this cohort. Repeated-measures ANOVA 
indicated a significant overall difference between CSF and plasma profiles (F=32.75,p<0.001). Paired 
comparisons between CSF and plasma values indicated that IL-8 was significantly higher, while IFN-
γ, IL-10 and TNF-α were significantly lower, in CSF versus plasma following Bonferroni correction 







CSF cytokines and neurodegeneration-associated proteins  
Alpha synuclein and amyloid beta(1-42) were the most abundant measured neurodegeneration-
associated proteins in CSF, whereas total tau and phospho-tau were present at low concentrations 
(Figure 1B). Bivariate correlation analyses between all measured CSF neurodegeneration-associated 
proteins and CSF cytokines revealed significant relationships between alpha-synuclein and amyloid 
beta(1-42) (Pearson’s r=0.499,p=0.004), total tau and IL-1β (Pearson’s r=0.554,p=0.002), total tau and 
IL-8 (Pearson’s r=0.591,p<0.001), and phospho-tau and IL-2 (Pearson’s r=-0.667,p=0.001)(Table 
S1)(Figure 1D-G). 
 
Multivariate linear regression analyses with each neurodegeneration-associated protein as the 
dependent variable confirmed significant positive relationships between tau and IL-8 
(B=0.779,p=0.001), tau and IL-1β (B=0.338,p=0.041), and alpha-synuclein and amyloid beta(1-42) 
(B=0.605,p=0.010), with age included as covariate (Table 1). 
 
 
CSF markers and clinical variables 
Bivariate correlation analyses revealed a significant relationship between semantic fluency and alpha 
synuclein which withstood  correction for multiple testing (r=-0.53,p=0.003) as well as nominally 
significant associations (p<0.05) between semantic fluency and IL-6; ACE-R and IL-6; and age and 
both IFN-γ and IL-1β (Table S2). There were no associations with measures of motor severity.  
Multivariate linear regression analyses with semantic fluency and ACE-R score as dependent variables, 
including age as covariate, confirmed the significant relationship between semantic fluency and alpha-
synuclein (B=-8.82,p=0.023), but not the associations between ACE-R and CSF variables (Figure 





This study has demonstrated that the cytokine profile in PD CSF does not relate closely to that seen in 
the periphery, suggesting that factors within the CNS may play a role in influencing local CNS 
inflammation. In keeping with this, our data also revealed positive correlations between CSF 
proinflammatory cytokines (IL-8, IL-1β) and CSF total tau in PD. In addition, we have confirmed a 
positive correlation between CSF alpha-synuclein and amyloid beta(1-42) and found  a negative 





Previous studies investigating relationships between CSF and serum/plasma cytokines in PD have 
reported elevated TNF-α in CSF compared to serum and correlations between CSF and serum levels of 
IL-6, IL-1β and IL-10 in PD and controls[11]. The different findings compared to our study may reflect 
variations in cohort demographics, disease stage and methodology. The lack of CSF-peripheral cytokine 
correlations in our results suggests that central and peripheral cytokine levels may behave independently 
of each other and that CSF changes may not simply reflect passive diffusion of circulating cytokines to 
the CNS.   Contributory factors to CSF cytokine levels may include cytokine production from CNS 
cells (e.g.microglia, astrocytes and neurons), peripheral-derived immune cells trafficking into the CNS, 
and active  transport across the blood brain barrier[12]. Thus,  CSF cytokines may better reflect CNS 
pathology, compared to peripheral cytokines, which may be driven by factors including peripheral 
alpha-synuclein aggregation/pathology, systemic infections/inflammation and microbial changes (e.g. 
gut microbiome)[13], with separate relevance to PD and disease progression[8].  
 
Within PD CSF, the ‘pro-inflammatory’ cytokines IL-1β and IL-8 correlated positively with total tau, 
while the ‘anti-inflammatory’ IL-2 correlated negatively with phospho-tau. Potential causal links 
between tau species and immune changes are unclear, but inflammation has been shown to  influence 
tau production/pathology[14]. CSF tau/phospho-tau levels have also been linked to cognitive 
progression and dementia within PD[3], while post-mortem and genetic studies have connected 
increased tau pathology and expression with higher risk of PD cognitive dysfunction/dementia[15][16]. 
The current findings linking CSF tau to inflammatory cytokines in PD may, therefore, be of some 
relevance in terms of the biological basis of cognitive heterogeneity within PD, regardless of findings 
in healthy controls. However, control studies will be essential in order to gain a more complete 
understanding of the tau-cytokine relationships within the CSF.  
 
 
The positive correlation between CSF alpha-synuclein and amyloid beta is consistent with previous 
studies[17]. Higher CSF alpha-synuclein levels are associated with worse (lower) semantic fluency, 
which is  predictive of the development of  PD-associated dementia[10]. Although the relationship 
between CSF alpha-synuclein and cognitive function in PD is complex, this result is consistent with 
previous studies  in similar-stage PD, linking  posterior cortical impairment  to increased CSF alpha-
synuclein[18]. These observations further support the importance of  alpha-synuclein in the 





Limitations of this study include the small sample size, lack of plasma samples in all subjects, and 
absence of matched healthy control samples. Furthermore, not all cytokines could be adequately 
measured in the CSF and plasma using this assay, and higher sensitivity assays may be needed for 
improved resolution of low-level cytokines.    However, the assessment of multiple neurodegeneration-
associated proteins and cytokines in simultaneously obtained CSF and plasma samples from a clinically 
well-characterised cohort has uniquely allowed interrelationships between these factors to be explored 
further in PD. Longitudinal assessments of these relationships in larger PD cohorts and matched healthy 
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Figure 1 – 
(A) Paired comparisons of analysed CSF and plasma cytokines in patients with PD (n=22).  
(B) Mean levels of CSF neurodegenerative proteins in patients with PD (n=35).  
(C) Scatter plot of Semantic Fluency score versus log10CSF alpha-synuclein. 
















Figure 1 – 
(A) Paired comparisons of analysed CSF and plasma cytokines in patients with PD (n=22).  
(B) Mean levels of CSF neurodegenerative proteins in patients with PD (n=35).  
(C) Scatter plot of Semantic Fluency score versus log10CSF alpha-synuclein. 





Variable Beta Coefficient (B) Significance 95% Confidence Interval for B 
Lower Upper 
Dependent variable - 
log10 CSF total tau 
    
Age 0.001 0.869 -0.008 0.009 
log 10 CSF IL-1β 0.338 0.041* 0.014 0.661 
log 10 CSF IL-8 0.779 0.001* 0.332 1.225 
     
Dependent variable - 
log10 CSF phospho-tau 
    
Age 0.002 0.874 -0.020 0.024 
log 10 CSF IL-1β -0.499 0.122 -1.150 0.152 
log 10 CSF IL-2 -0.692 0.104 -1.548 0.164 
log 10 CSF TNF-α -0.197 0.606 -1.005 0.610 
     
Dependent variable - 
log10 CSF alpha-
synuclein 
    
Age 0.007 0.455 -0.011 0.024 
log10 CSF amyloid 
beta(1-42) 
0.595 0.011* 0.144 1.046 
 
 
Table 1 - Linear regression analysis, with log 10 CSF total tau, log 10 CSF phospho-tau and log 10 CSF 


















Factors (log10) CSF cytokine or neurodegeneration-




CSF alpha-synuclein log10 CSF amyloid beta 0.499 0.004* 
CSF amyloid beta(1-
42) 
log10 CSF IL-4 -0.731 0.025 
CSF tau 
 
log10CSF IL-1β 0.554 0.002* 
log10CSF IL-8 0.591 <0.001* 
CSF phospho-tau 
 
log10CSF IL-1β -0.537 0.022 
log10CSF IL-2 -0.667 0.001* 
log10CSF TNF-α -0.456 0.043 
 
Table S1 - Summary of significant correlations between neurodegeneration-associated proteins and 
























Clinical Variable CSF marker Correlation 
(Pearson’s r) 
Significance (p) 
Semantic Fluency log10CSF IL-6 0.418 0.021 
log10 CSF alpha-synuclein -0.530 0.003* 
ACE-R score log10CSF IL-6 0.366 0.043 
Age log10CSF IFN-γ -0.410 0.027 
log10CSF IL-1β -0.369 0.049 
 
Table S2 – Significant correlations between clinical variables and CSF markers on bivariate analysis. 





Variable Beta Coefficient (B) Significance 95% Confidence Interval for B 
Lower Upper 
Dependent variable – 
ACE-R 
    
Age -0.408 0.058 -0.830 0.014 
log10CSF IL-6 14.006 0.080 -1.784 29.797 
     
Dependent variable – 
Semantic fluency 
    
Age -0.273 0.215 -0.714 0.169 
log10CSF IL-6 10.184 0.129 -3.178 23.546 
log10CSF alpha-synuclein -8.825 0.023* -16.346 -1.304 
 
 
Table S3 - Linear Regression with ACE-R score and semantic fluency as the dependent variables.  
*p<0.05.  
 
 
 
 
 
